Prof Dr Andres Pichon-Riviere

Director of the Health Economics and Technology Assessment Department at the IECS


Prof. Andres Pichon-Riviere (MD Msc PhD), is a Physician, graduated from the University of Buenos Aires (UBA). He has a Master of Sciences in Clinical Epidemiology from Harvard University and a PhD in Public Health (UBA).  

Andres is the Director of the Health Economics and Technology Assessment Department at the Institute for Clinical Effectiveness and Health Policy (IECS), an independent, non-for-profit organization devoted to Public Health research in Latin America and a WHO/PAHO collaborating center. He is also Full Professor of Public Health at the University of Buenos Aires, researcher at the National Scientific and Technical Research Council (CONICET), and Director of the courses of HTA for Decision Makers, HTA Postgraduate Course, and Economic Evaluation Modeling Introductory and Advanced Courses. 

He has conducted several training, research, and implementation projects in cooperation with government agencies, academic and private institutions in Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, El Salvador, Ecuador, Honduras, India, Mexico, Nigeria, Panama, Peru, Uruguay, and Venezuela. In 2008 was awarded the Global Health Leadership Award from the Global Health Research Initiative in recognition of his career in public health in Latin America. 

He was Vice-Chair of the International Network of Agencies for Health Technology Assessment (INAHTA) between 2010 and 2014, and member of the board of Directors of Health Technology Assessment International (HTAi) between 2012 and 2015. 

His recent work has involved the development of priority setting mechanisms and health benefits packages, and the establishment and training of health technology assessment agencies in developing countries. His most recent research has focused on the cost-effectiveness of vaccines, public health interventions, and oncologic drugs; cost-effectiveness thresholds, and in the analysis of the health and economic impact of public policies in the area of chronic diseases.